Compare CHE & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHE | APGE |
|---|---|---|
| Founded | 1970 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.7B |
| IPO Year | 1994 | 2023 |
| Metric | CHE | APGE |
|---|---|---|
| Price | $433.06 | $80.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $501.50 | $109.67 |
| AVG Volume (30 Days) | 193.5K | ★ 695.9K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.57% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.84 | N/A |
| Revenue | ★ $2,529,978,000.00 | N/A |
| Revenue This Year | $6.56 | N/A |
| Revenue Next Year | $6.23 | N/A |
| P/E Ratio | $90.74 | ★ N/A |
| Revenue Growth | ★ 4.06 | N/A |
| 52 Week Low | $365.21 | $34.34 |
| 52 Week High | $572.23 | $95.32 |
| Indicator | CHE | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 58.18 | 47.84 |
| Support Level | $423.89 | $80.52 |
| Resistance Level | $455.83 | $86.42 |
| Average True Range (ATR) | 11.55 | 4.54 |
| MACD | -0.83 | -0.34 |
| Stochastic Oscillator | 68.65 | 44.24 |
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.